Targeting this signaling axis via CCR2 blockade or CCL2-neutralizing antibodies has been shown to slow tumor progression and shunt TAMs from the TME in several preclinical tumor models, including pancreatic cancer in vivo [35,36,37]. This evidence concerns the gene CCR2 and neoplasm.